Initial versus sequential adjuvant aromatase inhibitor therapy: A review of the current data

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2479-2487

  Ellis, Matthew J ^a,b   Rigden, Caron E ^b  

^a Washington University in St Louis School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE FREE SURVIVAL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HEALTH CARE COST; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MODEL; MONOTHERAPY; OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; VASOMOTOR REFLEX;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; NITRILES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TRIAZOLES;

EID: 33846000608     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154150     Document Type: Review

References (47)

1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29
2. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005;16:1569-83
3. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology - Version 2.2006. 12-5-05 ©2005 National Comprehensive Cancer Network, Inc.
4. Howell A; on behalf of the ATAC Trialists' Group. The ATAC (Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer updated efficacy results based on a median follow-up of 5 years. Lancet 2005;365:1225-6
5. Thürlimann B, Keshaviah A, Coates AS, et al.; the Breast International Group [BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2005;353:2747-57
6. Coombes RC, Paridaens R, Jassem J, et al.; for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 2006;24(18S):933s [abstract LBA527]
7. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46
8. McArthur HL, Olivotto I, Gelmon KA, et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 2005;94(Suppl 1):S124 [abstract 3001]
9. Baum M, Buzdar A, Cuzick J, et al.; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10
10. Howell A. The ATAC (Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 5 years. Presented at the 24th Annual San Antonio Breast Cancer Symposium, December 2004 [poster 1]
11. Anastrozole (Arimidex) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, 2005
12. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7
13. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005:94(Suppl 1):S13 [abstract 44]
14. Jakesz R, Jonat W, Gnant M, et al.; on behalf of the ABCSG, the GABG. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62
15. Letrozole (Femara) package insert. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 2005
16. Letrozole European SPC. 2006. Available at: http://emc.medicines.org.uk/ emc/industry/default.asp?page=displaydoc.asp&documentid=3845
17. Exemestane (Aromasin) package insert. Pfizer Inc, New York, NY, 2005
18. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23;5138-47
19. Mouridsen H, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41:1678-89 [Epub November 25, 2004]
20. Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. Breast Cancer Res Treat 2005;94(Suppl 1):S11 [abstract 18]
21. Coombes RC, Hall E, Snowdon CF, Bliss JM. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;88:S7 [abstract 3]
22. Pritchard KI. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol 2005;23:4850-2 [Epub July 11, 2005]
23. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005;94 (Suppl 1):S10 [abstract 13]
24. Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005;95:143-9 [erratum in: J Steroid Biochem Mol Biol 2006;98:180 (Epub June 2, 2005)]
25. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Nad Cancer Inst 2005;97:1262-71
26. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
28. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women's Health Issues 2001;11:95-102
29. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial [The Scottish Cancer Trials Breast Group]. Br Med J 1995;311:977-80
30. Nordenskjold B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97:1609-10
31. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261-71
32. Distler W.; on behalf of the ATAC Trialists' Group. Safety and tolerability data from the ATAC trial after completion of 5 years adjuvant treatment. Breast 2005;14(Suppl 1):S51 [abstract P128]
33. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910-7
34. Medical Review of ATAC. Approval Package for Application Number 20-541/S-010. Anastrozole Efficacy Supplement Clinical Review 2002. [part 1; page 19 available at: http://www.fda.gov/cder/foi/nda/2002/20-541s010_Arimidex. htm] [accessed April 14, 2006]
35. Houghton J.; on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005:23(Suppl 16):24S [abstract 582]
36. Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005;23:5178-87 [Epub July 5, 2005]
37. Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 2005;25(16 Suppl):43S [abstract 658]
38. Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res 2006;12:1049s-1055s
39. Cykert S, Phifer N, Hansen C. Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 2004;104:433-42
40. Karnon J, Delea TE, Barghout V, et al. Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective. Breast Cancer Res Treat 2005;94(Suppl 1):S104 [abstract 2058]
41. Thompson D, Taylor DCA, Montoya EL, et al. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 2005;94(Suppl 1): S218 [abstract 5037]
42. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004;101:1311-22
43. Younis T, Rayson D, Dewar R, Skedgel C. Modeling for cost-effective strategies in adjuvant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors. Breast Cancer Res Treat 2005;94(Suppl 1):S237 [abstract 5089]
44. Delea TE, Karnon J, Thomas SK, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Res Treat 2005;94(Suppl 1):S102 [abstract 2054]
45. Risebrough NA, Verma S, Trudeau M, et al. Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective. Breast Cancer Res Treat 2005;94(Suppl 1): S101 [abstract 2050]
46. Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2005;17:217-25 [Epub Nov 2, 2005]
47. De Boer R, Burris H, Monnier A, et al.; on behalf of the H2H Trial Steering Committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc Am Soc Clin Oncol 2006;24:582s [abstract 10672]